Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oncogenic proteins and prognostic correlations in breast cancer.
Molina R, Filelia X, Segui MA, Climent MA, Pérez-Picañol E, Alonso C, Jo J, Ojeda B, Tandon AK, Ballesta AM. Molina R, et al. Among authors: ojeda b. In Vivo. 1993 Nov-Dec;7(6B):585-9. In Vivo. 1993. PMID: 7910764 Review. No abstract available.
Breast cancer in the elderly.
Bellet M, Alonso C, Ojeda B. Bellet M, et al. Among authors: ojeda b. Postgrad Med J. 1995 Nov;71(841):658-64. doi: 10.1136/pgmj.71.841.658. Postgrad Med J. 1995. PMID: 7494769 Free PMC article. Review.
Male breast cancer. Report of a series of 50 cases.
Izquierdo MA, Alonso C, De Andres L, Ojeda B. Izquierdo MA, et al. Among authors: ojeda b. Acta Oncol. 1994;33(7):767-71. doi: 10.3109/02841869409083946. Acta Oncol. 1994. PMID: 7993644
Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.
Gallardo A, Lerma E, Escuin D, Tibau A, Muñoz J, Ojeda B, Barnadas A, Adrover E, Sánchez-Tejada L, Giner D, Ortiz-Martínez F, Peiró G. Gallardo A, et al. Among authors: ojeda b. Br J Cancer. 2012 Apr 10;106(8):1367-73. doi: 10.1038/bjc.2012.85. Epub 2012 Mar 27. Br J Cancer. 2012. PMID: 22454081 Free PMC article.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
97 results